AAOS22: Catalyst Ortho to Debut Archer 3D Targeting Planning

Upper extremity orthopedics firm Catalyst OrthoScience has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its Archer 3D Targeting planning software for shoulder arthroplasty. The tech is licensed in partnership with 3D-Shoulder.
 
Archer 3D Targeting can plan for both anatomic and reverse shoulder surgeries. The tool gives shoulder surgeons an advanced understanding of each patient’s unique pathology and developed a custom surgical plan before the procedure. The software uses acquisitions like the best fit sphere to initially place implants, which surgeons can further refine.
 
Catalyst will preview Archer 3D Targeting and provide demos with Archer total and reverse shoulder systems at this week’s American Academy of Orthopaedic Surgeons (AAOS) meeting at booth #2408.
 
“3D planning has completely changed my approach to planning for my shoulder arthroplasty cases,” Matthew A. Kippe, MD, sports medicine and shoulder surgeon, Hawthorn Medical Associates, told the press. “I can now better understand the deformity associated with certain arthritic conditions and more accurately place components in order to ensure better functional outcomes and perhaps improve longevity.”
 
“3D planning has become the gold standard for shoulder arthroplasty, and the addition of the Archer 3D Targeting software further expands Catalyst’s ability to offer unique and innovative solutions for surgeons and their patients,” added Joseph Gentile, MD, orthopedic surgeon, Novant Health Orthopedics & Sports Medicine.